

Health Care: Drugs
Halozyme Therapeutics Inc. (HALO: NASDAQ)
$7.57 -0.39 | -4.90%
05/20/13 - 04:00 PM ET
Insider Trading
 |
| Historical Data |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
4 Mo. Ago |
5 Mo. Ago |
6 Mo. Ago |
| Net Insider Transaction |
20,000 |
105,000 |
85,000 |
85,000 |
22,000 |
22,000 |
216,189 |
| Shares Bought |
20,000 |
105,000 |
85,000 |
85,000 |
22,000 |
22,000 |
216,189 |
| Shares Sold |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Institutional Trading
 |
| Historical Data |
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
4 Mo. Ago |
5 Mo. Ago |
6 Mo. Ago |
| Total Shares Held |
67.63M |
71.40M |
71.04M |
72.39M |
74.22M |
73.60M |
74.34M |
| Shares Bought |
5.86M |
5.44M |
5.52M |
5.90M |
8.60M |
7.59M |
7.53M |
| Shares Sold |
17.06M |
13.08M |
12.97M |
13.08M |
8.38M |
10.50M |
10.54M |
Partner Headlines for HALO
- Halozyme Therapeutics Earnings: Here’s Why Investors are Ambivalent Now - Wall St. Cheat Sheet 05.08.13 | 07:05 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus - Benzinga 03.22.13 | 04:03 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- After Hours Most Active for Aug 1, 2012 : SAN, GMCR, NOK, FSLR, BBVA, SBUX, BAC, JNJ, LEN, HALO, QQQ, SPLS - NASDAQ 08.01.12 | 08:08 pm
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- Healthcare Biz Recap: GlaxoSmithKline BUYS Drugs, Sanofi Gains Traction - Wall St. Cheat Sheet 06.12.12 | 06:06 am